Pfizer Inc. (NYSE: PFE) reported its second quarter 2025 earnings results today. Revenues were $14.7 billion, up 10% year-over-year. Reported net income
PFE Earnings: All you need to know about Pfizer’s Q2 2025 earnings results
Categories
pharmaceuticals
BIIB Earnings: Highlights of Biogen’s Q2 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) on Thursday reported higher revenues and adjusted profit for the second quarter of 2025. The company
Key highlights from AbbVie’s (ABBV) Q2 2025 earnings results
AbbVie (NYSE: ABBV) reported its second quarter 2025 earnings results today. Worldwide net revenues were $15.4 billion, up 6.6% on a reported
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales
Merck & Co. Inc. (NYSE: MRK) on Tuesday reported lower sales and adjusted earnings for the second quarter of 2025. The company
Abbott Laboratories (ABT) Q2 2025 sales and earnings beat estimates
Abbott Laboratories (NYSE: ABT) on Thursday announced financial results for the second quarter of fiscal 2025, reporting an increase in sales and
Key highlights from Johnson & Johnson’s (JNJ) Q2 2025 earnings results
Johnson & Johnson (NYSE: JNJ) reported its second quarter 2025 earnings results today. Reported sales increased 5.8% year-over-year to $23.7 billion. Operational
Molina Healthcare reports preliminary Q2 2025 financial results
Molina Healthcare Inc. (NYSE: MOH), a managed care company focused on providing healthcare services to low-income individuals, on Monday reported preliminary results for
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing
Earnings Summary: Henry Schein (HSIC) reports higher Q1 2025 profit
Henry Schein, Inc. (Nasdaq: HSIC), a provider of healthcare solutions to office-based dental and medical practitioners, Monday reported an increase in net income
Earnings Summary: Cigna Group (CI) reports 14% growth in Q1 2025 revenue
The Cigna Group (NYSE: CI), a healthcare company focused on medical insurance and related services, reported results for the first quarter of 2025.
BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year decrease in adjusted profit for the first quarter of 2025, despite an
Key highlights from Pfizer’s (PFE) Q1 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its first quarter 2025 earnings results today. Revenues decreased 8% year-over-year to $13.7 billion. GAAP net income
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops
Bristol Myers Squibb (NYSE: BMY) reported net profit for the first quarter of 2025, compared to a loss last year. The biotechnology
MRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimates
Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q1 2025 financial results
Johnson & Johnson (NYSE: JNJ) reported its first quarter 2025 earnings results today. Reported sales increased 2.4% year-over-year to $21.9 billion. Operational
UNH Earnings Preview: Will UnitedHealth’s Q1 earnings beat expectations?
Like many insurance companies, UnitedHealth Group (NYSE: UNH) generally demonstrates the ability to remain relatively resilient during economic downturns, mainly due to
Deals and R&D in focus as Johnson & Johnson gears up for Q1 earnings
For Johnson & Johnson (NYSE: JNJ), investments in its pipeline and exiting lower priority businesses remain central to its strategy in the
AngioDynamics (ANGO) Q3 2025 loss narrows; sales down 4%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) Wednesday reported a narrower net loss for the third quarter of 2025. Revenues decreased by
OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness
OS Therapies (NYSE: OSTX) is a cancer immunotherapy company engaged in the development of new treatments for osteosarcoma and other solid tumors.
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance
Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided cautious first-quarter